Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...
Two recent analyses, published in European Urology, 6,7 claim to give a deeper insight into the clinical efficacy of intravesical BCG as compared with mitomycin C chemotherapy. The first, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback